Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the
efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified
(IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia
Gravis (MG).
Phase:
Phase 2
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC